Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for Hard-to-Treat lymphoma

NCT ID NCT03930953

Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental oral drug, CC-99282, in people with non-Hodgkin lymphoma that has come back or stopped responding to treatment. The drug is given alone or with other lymphoma medicines. The main goals are to check safety and find the best dose, while also seeing if it helps shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 438 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2019

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * History of Non-Hodgkin's Lymphoma (NHL) with relapsed or refractory disease. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. Exclusion Criteria * Life expectancy ≤ 2 months. * Received prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to starting CC-99282, whichever is shorter. * Is on chronic systemic immunosuppressive therapy or corticosteroids or has clinically significant graft-versus-host disease (GVHD). * Impaired cardiac function or clinically significant cardiac disease. * Other protocol-defined inclusion/exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphoma, non-Hodgkin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

follicular lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma Recurrence relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoma, non-Hodgkin

Contacts and locations

Locations

  • Local Institution - 101

    Houston, Texas, 77030, United States

  • Local Institution - 102

    Tampa, Florida, 32207, United States

  • Local Institution - 103

    Hackensack, New Jersey, 07601, United States

  • Local Institution - 104

    St Louis, Missouri, 63110, United States

  • Local Institution - 107

    Rochester, Minnesota, 55905, United States

  • Local Institution - 108

    Overland Park, Kansas, 66210, United States

  • Local Institution - 109

    Scottsdale, Arizona, 85259, United States

  • Local Institution - 111

    Jacksonville, Florida, 32224, United States

  • Local Institution - 150

    Jerusalem, 91120, Israel

  • Local Institution - 151

    Petah Tikva, 49100, Israel

  • Local Institution - 152

    Ramat Gan, 52621, Israel

  • Local Institution - 201

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 253

    Buenos Aires, C1431FWO, Argentina

  • Local Institution - 254

    Pilar, Buenos Aires, 1629, Argentina

  • Local Institution - 255

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1118AAT, Argentina

  • Local Institution - 301

    Barcelona, 08035, Spain

  • Local Institution - 302

    Madrid, 28040, Spain

  • Local Institution - 303

    Málaga, 29010, Spain

  • Local Institution - 304

    Madrid, 28046, Spain

  • Local Institution - 305

    Salamanca, 37007, Spain

  • Local Institution - 306

    Badalona (Barcelona), 08916, Spain

  • Local Institution - 350

    Santiago, RM, 7560908, Chile

  • Local Institution - 352

    Santiago, Santiago Metropolitan, 8320000, Chile

  • Local Institution - 353

    Santiago, Santiago Metropolitan, 7500921, Chile

  • Local Institution - 354

    Santiago, Metropolitana de Santiago, 7580206, Chile

  • Local Institution - 355

    Recoleta, Santiago Metropolitan, 842 0383, Chile

  • Local Institution - 401

    Villejuif, 94805, France

  • Local Institution - 402

    Pierre-Bénite, 69495, France

  • Local Institution - 403

    Créteil, 94010, France

  • Local Institution - 404

    Rouen, 76038, France

  • Local Institution - 405

    Paris, 75010, France

  • Local Institution - 406

    Lille, 59037, France

  • Local Institution - 407

    Bordeaux, 33076, France

  • Local Institution - 408

    Toulouse, 31200, France

  • Local Institution - 409

    Montpellier, 34295, France

  • Local Institution - 450

    São Paulo, São Paulo, 05651-901, Brazil

  • Local Institution - 451

    São Paulo, 01401-002, Brazil

  • Local Institution - 452

    São Paulo, 1246000, Brazil

  • Local Institution - 453

    Porto Alegre, Rio Grande do Sul, 90610-000, Brazil

  • Local Institution - 501

    Bergamo, 24127, Italy

  • Local Institution - 502

    Naples, 80131, Italy

  • Local Institution - 503

    Milan, 20162, Italy

  • Local Institution - 504

    Bologna, 40138, Italy

  • Local Institution - 506

    Pavia, 27100, Italy

  • Local Institution - 550

    Seoul, 06351, South Korea

  • Local Institution - 551

    Seoul, 03080, South Korea

  • Local Institution - 552

    Seoul, 06591, South Korea

  • Local Institution - 553

    Busan, 47392, South Korea

  • Local Institution - 601

    Copenhagen, 2100, Denmark

  • Local Institution - 602

    Aarhus, 8200, Denmark

  • Local Institution - 603

    Vejle, 7100, Denmark

  • Local Institution - 650

    Shanghai, Shanghai Municipality, 200025, China

  • Local Institution - 651

    Tianjin, Tianjin Municipality, 300060, China

  • Local Institution - 653

    Beijing, Beijing Municipality, 100020, China

  • Local Institution - 655

    Zhengzhou, Henan, 450000, China

  • Local Institution - 657

    Guangzhou, Guangdong, 510080, China

  • Local Institution - 659

    Guangzhou, 510060, China

  • Local Institution - 660

    Wuhan, Hubei, 430079, China

  • Local Institution - 662

    Shenyang, Liaoning, 110001, China

  • Local Institution - 663

    Shenyang, Liaoning, 110022, China

  • Local Institution - 701

    Salzburg, 5020, Austria

  • Local Institution - 703

    Vienna, 1090, Austria

  • Local Institution - 704

    Sankt Pölten, 3100, Austria

  • Local Institution - 802

    Edinburgh Scotland, EH4 2XU, United Kingdom

  • Local Institution - 803

    Southhampton, SO01 6YD, United Kingdom

  • Local Institution - 902

    Leuven, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.